Background-Genome-wide association studies (GWAS) have identified many single-nucleotide polymorphisms (SNPs) associated with coronary heart disease (CHD) or CHD risk factors (RF). Using a case-cohort study within the prospective Cardiovascular Registry Maastricht (CAREMA) cohort, we tested if genetic risk scores (GRS) based on GWAS-identified SNPs are associated with and predictive for future CHD. Methods and Results-Incident cases (nϭ742), that is, participants who developed CHD during a median follow-up of 12.1 years (range, 0.0 -16.9 years), were compared with a randomly selected subcohort of 2221 participants selected from the total cohort (nϭ21 148). We genotyped 179 SNPs previously associated with CHD or CHD RF in GWAS as published up to May 2, 2011. The allele-count GRS, composed of all SNPs, the 153 RF SNPs, or the 29 CHD SNPs were not associated with CHD independent of CHD RF. The weighted 29 CHD SNP GRS, with weights obtained from GWAS for every SNP, were associated with CHD independent of CHD RF (hazard ratio, 1.12 per weighted risk allele; 95% confidence interval, 1.04 -1.21) and improved risk reclassification with 2.8% (Pϭ0.031). As an exploratory approach to achieve weighting, we performed least absolute shrinkage and selection operator (LASSO) regression analysis on all SNPs and the CHD SNPs. The CHD LASSO GRS performed equal to the weighted CHD GRS, whereas the Overall LASSO GRS performed slightly better than the weighted CHD GRS. Conclusions-A GRS composed of CHD SNPs improves risk prediction when adjusted for the effect sizes of the SNPs.
C oronary heart disease (CHD) is a complex disease influenced by both lifestyle and genetic factors. During past years, genome-wide association studies (GWAS) have identified multiple common single-nucleotide polymorphisms (SNPs) that are robustly associated with the risk of CHD [1] [2] [3] [4] [5] or CHD risk factors, including blood pressure 6, 7 and plasma lipid levels. 8, 9 It was hoped that GWAS would identify SNPs that were useful in predicting CHD risk.
Individually, however, these SNPs have a relatively small effect size. Greater effect sizes may be expected for genetic risk scores (GRS) that comprise the cumulative effect of individual SNPs. 10, 11 
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Two previous prospective studies investigated the association of a GRS with incident CHD. 12, 13 Paynter et al 12 found that an allele-count GRS based on 101 published GWAS SNPs known to be associated with cardiovascular disease (CVD) and its intermediate risk factors was associated with a CVD in US women but not independent from risk factors used in the ATP III or Reynolds risk score. The association was somewhat stronger for an allele-count GRS based on a subset of 12 SNPs selected for their association with clinical cardiovascular end points. 12 In a recent Finnish cohort, a weighted GRS based on 13 GWAS-identified, CHDassociated SNPs was independently associated with 10-year incidence of CHD. 13 In our study, we composed 3 allele-count GRS on the basis of 179 SNPs that were associated with CHD or CHD risk factors in GWAS published up to May 2, 2011 ; that is an Overall GRS based on all 179 SNPs, a Risk Factor GRS based on 153 SNPs associated with CHD risk factors, and an allele-count CHD GRS based on 29 SNPs associated with CHD. In addition, a weighted CHD GRS, with the weights obtained from 2 published GWAS, was constructed. As an exploratory analysis, we constructed a least absolute shrinkage and selection operator (LASSO) GRS based on all 179 SNPs and on the 29 CHD SNPs. We investigated their predictive value for CHD during a median follow-up of 12.1 years in a population-based setting.
Methods

Study Population
The Cardiovascular Registry Maastricht (CAREMA) study population has been described before. 14 In short, the study participants living in the Maastricht region were selected from 2 large monitoring projects in The Netherlands: the monitoring project on CVD risk factors (PPHVZ), 1987 to 1991, and the monitoring project on chronic disease risk factors (MORGEN Project), 1993 to 1997, including the transition year (1992) between these 2 projects. Each year, a random sample of people aged between 20 and 59 years were selected from municipal registries of Maastricht and surrounding communities. In total, 21 662 men and women, born between 1927 and 1997, were included in this study, and 21 148 participants (97.6%) gave informed consent to retrieve information from the municipal population registries and from their general practitioner and specialist.
Cardiological Follow-Up
The cardiological follow-up has been described earlier. 14 In short, by linking the cohort to the hospital information system of the University Hospital Maastricht, 97.6% of the cohort members could be found (nϭ20 632). Next, these subjects were linked to the cardiology information system of the department of cardiology. For participants who died, the cause of death was obtained from Statistics Netherlands. In addition, the CAREMA cohort was linked to the hospital discharge registry of the University Hospital Maastricht to enlarge the completeness of the cardiological follow-up.
All participants who were younger than 30 years of age at baseline (nϭ3505), who had an acute myocardial infarction (MI), unstable angina pectoris, a coronary artery bypass graft or a percutaneous transluminal coronary angioplasty before baseline (nϭ187), were lost to follow-up (nϭ17), or were included in the transition year 1992 (nϭ2203), were excluded from further analysis. From the fully eligible CAREMA cohort, a subcohort of 2221 participants was drawn randomly. No blood was available for 188 participants, DNA extraction was unsuccessful in 49 participants, and no complete information on TRFs was available for 71 participants. Thus, the available subcohort group consisted of 1913 participants.
Case-Cohort Design
Determination of Risk Factors
At baseline, all participants filled in a questionnaire on medical history, parental history of MI, and lifestyle factors. During a medical examination at baseline, information was collected on blood pressure, height, and weight. In addition, nonfasting blood samples were collected, using EDTA tubes. The blood was centrifuged for 10 minutes at 1000 rpm, fractioned into blood plasma, white blood cells fractions (buffy coats), and erythrocytes and subsequently stored at Ϫ20°C. Within 3 weeks, the blood plasma samples were transported to the Lipid Reference Laboratory of the University Hospital Dijkzigt (LRL) in Rotterdam, where total and HDL cholesterol levels were determined, using a CHOD-PAP method. 15 
SNP Selection
Using the GWAS Catalog 16 (www.genome.gov/gwastudies; accessed May 2, 2011), 248 SNPs were identified that showed an association with CHD or its intermediate risk factors (ie, blood pressure, anthropomorphic traits (BMI, waist circumference, and waist-to-hip ratio), blood lipid levels, and type 2 diabetes) in at least 2 GWA studies or in a meta-analysis at a genome-wide significance levels (PϽ5*10 Ϫ8 ). For the SNPs that were in perfect linkage disequilibrium (LD) (DЈϭ1; R 2 ϭ1) with each other, 1 of them was excluded (nϭ22). For 29 SNPs, it was impossible to design primers or they did not fit in the assay designs, leaving 197 SNPs for genotyping (see online-only Data Supplement Table I ).
DNA Extraction and Genotyping
DNA was extracted from the buffy coats, using a standard procedure. 17 The resulting DNA pellet was dissolved in TE buffer and DNA concentrations were determined using the Nanodrop ND1000 Spectrophotometer. SNPs were genotyped, using the iPLEX Gold chemistry of Sequenom's MassARRAY platform (San Diego, CA). Sequenom's MassARRAY Assay Design 3.1 Software was used for assay designs, and Sequenom's SpectroTyper 4.0 software was used to call genotypes automatically, followed by manual review. Nine SNPs failed genotyping (eg, no PCR product or an abnormal cluster plot), 2 SNP were removed because of a success rate Ͻ90%, and 7 SNPs were removed because they were out of Hardy-Weinberg equilibrium (PϽ0.001) calculated in the subcohort, leaving 179 SNPs for analysis (online-only Data Supplement Table II ). Individuals were removed when their success rate was Ͻ80%, leaving 642 cases and 1905 subcohort members. The overall call rate for the remaining SNPs and individuals was 98.24%. For success rate per SNP, see online-only Data Supplement Table II .
Statistical Analysis
To impute missing genotypes (1.76%), a multiple imputation method was used (R packages mi v0.08 -08). Missing genotypes were imputed, where the chance of being a major homozygote, heterozygote, or minor homozygote depends on the distribution of the particular SNPs. This process was repeated 20 times; thus, 20 new datasets with nonmissing data were created. Next, all imputed datasets were analyzed as described below and the results from every imputed dataset were combined using the R package mitools (version
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2.0). For results on the nonimputed dataset, see online-only Data Supplement Table IV . We constructed 3 allele-count GRS and 1 weighted GRS. The first GRS compromised all 179 SNPs associated with CHD and its intermediate risk factors (Overall GRS). The rationale behind this GRS was to combine the information of all known SNPs associated with CHD or its intermediate risk factors and test its predictive value in a prospective cohort study. The second one consisted of the 153 SNPs associated with intermediate risk factors for CHD (Risk Factor GRS). This GRS was included to evaluate to what extent such SNPs could replace TRFs. The third GRS consisted of SNPs previously associated with CHD (CHD GRS). The reason for including this GRS (not diluted by SNPs, with only a small effect on TRFs) was to test if this GRS would associate with incident CHD and possibly improve risk prediction in addition to TRFs. A similar approach was used by Paynter et al, 12 although fewer SNPs associated with CHD or its intermediate risk factors were identified at that time. The fourth GRS contained the same 29 CHD SNPs, but every SNP was weighted according to its effect size (weighted CHD GRS) to allow the prediction to be based mainly on the most informative SNPs. For estimating the weights of the individual SNPs, the effect sizes were obtained from 2 large GWAS on CHD (see online-only Data Supplement Table III ). 4, 18 A similar approach was used by Ripatti et al. 13 We tested whether the 4 GRS were associated with future CHD, using Cox proportional hazards models with robust variance estimation to adjust for the case-cohort design according to the method of Prentice. 19 These models were used to estimate the 10-year risk of CHD, using a base model with and without each GRS. The base model consists of these TRFs: sex, current smoking, self-reported diabetes, parental history of MI, HDL cholesterol, total cholesterol, systolic blood pressure, and BMI. Age in years was used as the time-scale variable, and we adjusted for delayed entry. The same analyses were also done for every SNP separately.
Because of a change in scaling (the allele-count CHD GRS theoretically ranges from 0 to 58, whereas the weighted CHD GRS ranges from 0 to 22.14), the hazard ratio of a weighted GRS cannot be directly compared with an allele-count GRS. Thus, for comparing the effects of the different GRS, we calculated the z-scores for all GRS in all individuals and performed the above analysis on these standardized GRS.
To test if adding a GRS to the base model improved risk prediction, c-statistics, according the nonparametric method of De-Long et al 20 and the net reclassification improvement (NRI) as described by Pencina et al, 21 were used. The NRI was not directly applicable to our study because of noncases (nϭ550) who were censored (eg, due to mortality from causes other than CHD during the 10-year follow-up period) and cases (nϭ208) that got an event after 10 years of follow-up. 22 Therefore, cases who developed an event after 10 years of follow-up were treated as control subjects who left the study at 10 years of follow-up (nϭ208), which resulted in 434 cases and 2012 noncases. Next, we calculated a Kaplan-Meier curve for the subcohort. Based on this Kaplan-Meier curve, weights were assigned to every individual. Weights of zero were assigned to noncases who left the study before 10 years of follow-up (nϭ550). Using the 10-year risk estimates, subjects were divided into the following risk categories: 0% to Ͻ5%, 5% to Ͻ10%, 10% to Ͻ20%, and Ն20%, as previously applied. 12, 13 For all analyses, we used the software R (version 2.10.1, www.r-project.org) in combination with the package survival (version 2.35-8) for the Cox-proportional hazards models according to Prentice and the Kaplan-Meier curve. For estimating the c-statistics and corresponding probability values, we used the R package pROC (version 1.4.1).
GRS Based on LASSO Regression
Not all GWAS-identified SNPs may contribute to the risk of future CHD in our population-based, prospective study. 23 Therefore, as an exploratory analysis, we selected a subset of the most informative SNPs using LASSO regression, 24 in combination with 10-fold cross-validation to address the issue of internal validation. 24 -26 Using the LASSO approach, a subset of informative SNPs was extracted from the 29 CHD SNPs (CHD LASSO GRS) and the complete SNPs set (Overall LASSO GRS). Both GRS were subject to the same statistical analysis as for the previous four GRS. For the LASSO regression analysis, the R package penalized (version 0.9 -32), was used. See online-only Data Supplemental Methods for more detailed information about this analysis.
Results
Baseline Characteristics
The TRFs are associated with future CHD in the CAREMA study population (see Table 1 ). When all TRFs were entered into one Cox proportional hazards model, with age as the time-scale variable, BMI was no longer significantly associated with future CHD. 
Genetic Risk Scores
An Overall GRS was constructed of all the 179 SNPs, of which a detailed overview including their association with incident CHD before and after adjustment for TRFs, is presented in online-only Data Supplement Table IV . The Overall GRS had a mean value (SD) of 182.9 (9.2) for all participants, with a range from 142 to 217 risk alleles. As shown in Table 2 , this Overall GRS was associated with CHD with a hazard ratio (HR) of 1.02 per risk allele (95% confidence interval [CI], 1.01-1.03); after adjustment for TRFs, the effect size further attenuated (HR/risk allele, 1.01; 95% CI, 1.00 -1.02). As shown in Table 2 , the Risk Factor GRS constructed from the 153 SNPs selected for their previous association with CHD risk factors (blood pressure, anthropomorphic traits, blood lipid levels, and type 2 diabetes) was associated with future CHD (HR/risk allele, 1.02; 95% CI, 1.01-1.03) but not after adjustment for TRFs (HR/risk allele, 1.00; 95% CI, 0.99 -1.02).
Next, the CHD GRS constructed from the 29 SNPs selected for their previous association with CHD was investigated. The allele-count CHD GRS was associated with future CHD, with a HR of 1.04 per risk allele (95% CI, 1.01-1.07). After adjustment for TRFs, this GRS was no longer associated (HR, 1.03; 95% CI, 0.95-1.12). The CHD GRS that was weighted for previously reported effect sizes of the included SNPs, however, was associated with future CHD both before (HR, 1.15; 95% CI, 1.07-1.23) and after the adjustment for TRFs (HR, 1.12; 95% CI, 1.04 -1.21).
C-Indexes
The discriminatory capabilities of the 4 GRS without including other variables were low (c-indexϭ0.547 for the Overall GRS, 0.538 for the risk factor GRS, 0.527 for the CHD GRS, and 0.550 for the weighted CHD GRS) but all statistically significant (see Figure, E, and Table 3 ). As shown in the Figure and Table 3 , when using a prediction model based on all TRFs (c-indexϭ0.816), adding any of the 4 GRS did not improve risk discrimination.
Net Reclassification Improvement
We found no improvement in reclassification when the Overall GRS, the Risk Factor GRS, or the allele-count CHD GRS was added to the base model (Table 4 , for more details, see online-only Data Supplement Table VII , A through C). When we used the weighted CHD GRS, 8.1% of the participants were classified into a more appropriate risk category, but for 5.3% of the population the reclassification got worse; thus, the NRI improved with 2.8% (Pϭ0.031), which could be attributed to an improvement in reclassification for events (ie, individuals who did have a CHD event; NRIϭ2.5%, Pϭ0.040, see online-only Data Supplement Table VII, D).
GRS Based on LASSO Regression
As an exploratory analysis, we performed LASSO regression analysis on the 29 SNPs previously associated with CHD, extracting 3 SNPs with corresponding weights. These SNPs and their weights were used to compose a weighted GRS (see online-only Data Supplement Results and online-only Data Supplement Table VI for the included SNPs and their corresponding weights). This CHD LASSO GRS was associated with incident CHD (HR, 1.38; 95% CI, 1.21-1.57) and remained significantly associated after adjusting for TRFs (HR, 1.36; 95% CI, 1.21-1.52). The standardized HR of this CHD LASSO GRS (HR/sd increase, 1.27; 95% CI, 1.16 -1.40) is comparable to that of the weighted CHD GRS (HR/sd increase, 1.21; 95% CI, 1.10 -1.33). Next, we performed LASSO regression analysis on all SNPs, resulting in the extraction of 14 SNPs with corresponding weights (see †Increase in hazard ratio per standard deviation.
Figure.
Receiver-operator characteristic curves for coronary heart disease (CHD). Curves were based on the traditional risk factors (age, sex, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, current smoking, self-reported diabetes, and parental history of myocardial infarction) with and without each genetic risk score (GRS). The following GRS were included: A, Overall GRS; B, Risk Factor GRS; C, CHD GRS; D, Weighted CHD GRS; E, the CHD least absolute shrinkage and selection operator (LASSO) GRS; and F, the LASSO GRS. AUC indicates area under the curve. Supplement Table VI for the included SNPs and their weights). The LASSO Overall GRS based on these 14 SNPs and their weights was associated with incident CHD (HR, 1.48; 95% CI, 1.31-1.29) and remained significantly associated when adjusted for TRFs (HR, 1.39; 95% CI, 1.26 -1.53). As shown in Table 2 , the standardized HR of the LASSO GRS was higher than that of the weighted CHD GRS.
online-only Data Supplement Results and online-only Data
Discussion
Over the past 5 years, the pace of identification of genetic variants underlying susceptibility to CHD has rapidly increased, leading to an interest in investigating if and how this information may be used in improving CHD risk prediction. Therefore, we evaluated the predictive "potential " of various GRS constructed on the basis of 179 SNPs associated with CHD and/or intermediate CHD risk factors in published GWAS. The weighted CHD GRS, constructed from 29 SNPs previously associated with CHD, using information on effect sizes from 2 large GWAS on CHD, 4,18 was associated with incident CHD, the effect being independent from age, sex, current smoking, self-reported diabetes, parental history of MI, HDL cholesterol, total cholesterol, systolic blood pressure, and BMI. This weighted CHD GRS also improved risk reclassification but not discrimination above a model using only TRFs. The 3 allele-count GRS (ie, the Overall GRS, the Risk factors GRS and the CHD GRS) were associated with incident CHD but not independent of TRFs; neither did they improve risk prediction above a model using only TRFs. The lack of improvement in risk prediction may be related to the fact that most GWAS-identified SNPs have a very low effect size, and only a few SNPs have a higher effect size and as a result an allele-count GRS may be diluted. We observed that weighting SNPs according to their effect sizes may overcome this problem. However, it may not always be possible to provide weights to novel identified SNPs. To overcome this limitation and as an exploratory analysis, we used LASSO regression, which can be used to achieve data selection and shrinkage at the same time. With this approach, we extracted a subset of 3 SNPs from the 29 SNPs previously associated with CHD. This GRS performed equally compared with the weighted CHD GRS composed of all 29 CHD SNPs. Because it is impossible to apply weighting on the SNPs associated with intermediate CHD risk factors based on previously published studies, LASSO regression was used to select the set of best predicting SNPs from all 179 SNPs, resulting in a 14-SNP LASSO GRS. The association of this 14-SNP LASSO GRS with future CHD risk was stronger than the CHD LASSO GRS and modestly but significantly improved both risk discrimination and reclassification. With cross-validation, we have addressed the issue of internal validation. 27 Cross-validated LASSO regression, however, is exploratory and must be externally validated in independent, prospective cohort studies.
Our findings for the allele-count Overall GRS based on all 179 SNPs are in line with a recently published, large, prospective cohort study. 12 In this study, a GRS composed of 101 SNPs previously associated with CVD or an intermediate phenotype was not associated with CVD after adjustment for risk factors used in the ATP III or Reynolds risk score. 12 This GRS also did not improve risk discrimination or reclassification. 12 The allele-count CHD GRS was not associated with CHD after adjustment for TRFs in our population, which confirms findings in a recently published, large, prospective cohort study of women, where a GRS composed of 12 CVD-associated SNPs was associated with CVD but not after adjusting for TRFs. 12 A weighted GRS, composed of 13 SNPs associated with CHD and sharing 8 genetic variants with our CHD GRS, was tested in a large Finnish cohort study. 13 This GRS was associated with CVD after adjustment for TRFs, which confirms our finding for the weighted GRS. In a recently published meta-analysis of 14 case-control studies, a weighted GRS of 23 SNPs associated with CHD was constructed. This GRS was highly associated with CHD, although the outcome was not adjusted for TRFs. The currently tested weighted CHD GRS encompassing 29 SNPs was associated with incident CHD in our prospective casecohort also after adjustment for TRFs.
From our study, we can conclude the following. First, the 3 allele-count GRS, composed of common SNPs previously associated with CHD and/or intermediate CHD risk factors, currently has no value in predicting incident CHD compared with measuring classic biochemical parameters and systolic blood pressure measurement at one single point in time. Second, it might be important to account for the different effect sizes of SNPs in a GRS, given the fact that the weighted CHD GRS was still associated with CHD after adjustment for TRFs and the allele-count CHD GRS was not associated. These results are in line with a study by Davies et al, 23 in which they show that a weighted GRS outperforms allele counting. Third, when using the weighted CHD GRS in addition to TRFs and when accounting for the fact that using a new predictor also can deteriorate reclassification, 2.8% of the participants were placed in a more appropriate risk category. Fourth, 10-fold cross-validated LASSO regression possibly could be used for extracting a subset of SNPs from a larger set of SNPs, although this method must be externally validated in independent prospective cohort studies.
The SNPs that we used for constructing the GRS were detected in GWAS with large sample sizes. Our study has lower power to detect the small effect sizes, which will have contributed to our observation that most of SNPs were not significantly associated with CHD when analyzed individually. We did remove SNPs in complete LD but not the ones in high LD, which could bias the results of the Overall GRS and the Risk Factor GRS, depending on the regions that were over represented. For the allele-count and the weighted CHD GRS, this is not an issue because none of the included SNPs in the CHD GRS were in very high LD with each other. Also, for constructing the LASSO GRS, highly correlated SNPs were not a problem because penalized logistic regression methods, such as LASSO regression, only select 1 SNP from many correlated SNPs. 28 We have not externally validated the LASSO analysis method in an independent population and therefore we cannot say that this exploratory method applies to other populations.
In conclusion, the weighted CHD GRS, in contrast to the allele-count CHD GRS, was associated with future CHD independent of TRFs and improves risk reclassification. We conclude that it is important to adjust for the effect sizes of the different SNPs. If information on effect sizes is not available, LASSO regression analysis may be used to estimate these effect sizes. This method must be externally validated in independent prospective cohort studies
